Content highlights

Release date

August 2024

Updated throughout the year to reflect Clarivate's expert analysis of the latest major-market events

Geography

United States, EU5, Japan

Primary research

30 country-specific interviews with thought-leading medical oncologists

Supported by survey data collected for this and other Clarivate research

Epidemiology

Diagnosed incidence of NSCLC by country, histology, stage, and line of therapy, segmented into clinically and commercially relevant drug-treatable populations

Forecast

10-year, annualized, drug-level sales and patient share of key NSCLC therapies through 2033, segmented by brands / generics / biosimilars / relevant epidemiological subpopulations

Drug treatments

Coverage of key current and emerging therapies

Non-Small-Cell Lung Cancer
Spotlight on Disease Landscape & Forecast

Market outlook

The multibillion-dollar non-small-cell lung cancer (NSCLC) therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which gained label expansions in the resectable early-stage space in 2023, have broad applicability in many stages and settings of NSCLC and dominate the field. Biomarker-targeted therapeutics increasingly drive segmentation of the market, and this setting also saw further entrants in 2023 (Braftovi + Mektovi, Augtyro). Continued drug development in the biomarker and immune checkpoint inhibitor classes, plus expected new market entrants, will further drive competition in the commercially lucrative NSCLC market.

Questions answered

- How will the recent and expected new market entrants shape the treatment landscapes in the various settings and stages (I-IV) of NSCLC?
- Which therapies will dominate the commercially lucrative first-line metastatic NSCLC setting?
- What are the most promising pipeline products, and what will be their likely uptake and patient share in NSCLC?
- What are the NSCLC therapy market's key drivers and constraints, and how will the market evolve over the forecast period?

Product description

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.

Key features

Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.

Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Learn more about Clarivate's full suite of non-small-cell lung cancer solutions:

healthcare.support@clarivate.com | clarivate.com